Overview
4BIO Partners, LLP (the “firm” or the “Adviser”) is an SEC Registered Investment Adviser with
its principal place of business in the United Kingdom. The firm is owned by its three members,
Kieran Mudryy, Partner, Chief Compliance Officer, and Andrey Kozlov, Managing Partner and
Chief Financial Officer and Dmitry Kuzmin, Managing Partner and Chief Scientific Officer, and
is also registered with the Financial Conduct Authority FCA in the United Kingdom (Reference
Number 842764).
The Adviser provides investment advisory and management services to 4BIO Ventures II LP,
4BIO Ventures III LP and 4BIO Advanced Therapies Long Equity (the “Funds”) that are exempt
from registration under the Investment Company Act of 1940, as amended (the “1940 Act”) and
whose securities are not registered under the Securities Act of 1933, as amended (the “Securities
Act”), or under state securities laws, in reliance upon exemptions for transactions not involving a
public offering. Accordingly, to invest in the Funds, investors must be “accredited investors” as
defined in Regulation D of the Securities Act and some cases “qualified purchasers” under
Section 3(c)(7) of the Investment Company Act of 1940, as amended (the “Investment Company
Act”).
In accordance with the Funds’ respective investment objectives, as the Investment Manager and
the Investment
Adviser of the Funds, the Adviser’s services to the Funds include the
identification, evaluation and selection of investment opportunities for the Funds; performance of
due diligence in connection with such potential investments; negotiation of investment terms;
and monitoring the performance of the Funds’ portfolio.
The Adviser advises 4BIO Ventures II LP and 4BIO Ventures III LP on a discretionary basis in
accordance with the terms of the Management Deeds, funds’ Limited Partnership Agreement and
other funds governing documents.
The Adviser advises 4BIO Advanced Therapies Long Equity Fund on a non-discretionary basis
in accordance with the terms of the Investment Advisory Agreement, the Prospectus, the
Supplement and other fund’s governing documents.
The Adviser may serve as the investment adviser or general partner or establish a separate
general partner to the Funds in order to provide such services, which is responsible for the
operations of the Fund other than its investment decisions.
As of March 31, 2022, the Adviser manages and advises a total of $163,390,000 of Fund’s
assets, which includes uncalled commitments, co-investment amounts and undistributed capital
that has been redeployed, all of which is managed on a discretionary basis.
The Adviser does not participate in wrap fee programs.
(Item 5)